Tracer library / [131I]GV-620
[131I]GV-620
- Radionuclide
- I-131 t½ 11549 min
- Modality
- Therapy
- Production route
- —
- Stage
- Preclinical
- Syntheses indexed
- 1
What it is
Published syntheses
| Module | Cassette | Purification | Yield % | RCP % | Precursor / supplier | Source |
|---|---|---|---|---|---|---|
| Manual synthesis | — | HPLC+SPE | 78 ± 3% | 96 ± 5% | tin precursor 3 | 33601187 2021 Nucl Med Biol Iodine-131 (1 – 3 μL; 60–75 MBq), a solution of NCS in methanol (100 μL of 1 mg/mL) and acetic acid (20 μL) were added to 50 μg of the respective tin precursor - The RCY for the synthesis of [131I]GV-620 was 78 ± 3% (n = 6) and the RCP was 96 ± 5% |
Need this precursor?We can point you to suppliers for [131I]GV-620, or handle the enquiry for you.
Get in touchNotes
Added at stage 22: promoted from 'Reported once' (single-article, no diagnostic pair at discovery) because a full-text synthesis with extracted data exists in parsed-therapy.xlsx -- PMID(s): 33601187. Target/mechanism, clinical application, indications, approval and precursor fields still need per-agent research and are intentionally left empty. Stage set/updated at stage 39 from PMID 33601187: 'A series of paired-label biodistribution experiments were performed to compare each 211At-labeled PSMA ligand to its 131I-labeled counterpart in mice bearing subcutaneous PC3 PSMA+ PIP xenografts.'.